David Luo
Impact in
- Oncology top 5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
-
- Lung Cancer Treatments and Mutations
Papers in
-
- Immunotherapy and Immune Responses 3
- Immune Cell Function and Interaction 2
- Co-authors
- Pratik S. Multani (2 shared papers)Zachary Hornby (2 shared papers)Alona Muzikansky (1 shared paper)Zongli Zheng (1 shared paper)Anna F. Farago (1 shared paper)Manish R. Patel (1 shared paper)Todd Michael Bauer (1 shared paper)Daniel Botelho Costa (1 shared paper)
- Journals
- Frontiers in Immunology (2 papers)Vaccine (1 paper)Cancer Discovery (1 paper)Journal of the National Comprehensive Cancer Network (1 paper)Journal of Pharmacy Practice and Research (1 paper)
- Partner nations
- United StatesItalyChina
In The Last Decade
David Luo
15 papers receiving 1.3k citations
David Luo's Hit Papers
Peers
Comparison fields: 5 of 86
- Oncology 597
- Pulmonary and Respiratory Medicine 609
- Cancer Research 260
- Pathology and Forensic Medicine 197
- Genetics 103
Countries citing papers authored by David Luo
This map shows the geographic impact of David Luo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Luo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Luo more than expected).
Fields of papers citing papers by David Luo
This network shows the impact of papers produced by David Luo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Luo. The network helps show where David Luo may publish in the future.
Co-authors
The 25 scholars most cited alongside David Luo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1) Hit paper breakdown → | 2017 | 671 |
| 2 | 2015 | 225 | |
| 3 | 2015 | 195 | |
| 4 | 2015 | 67 | |
| 5 | 2017 | 52 | |
| 6 | 2001 | 34 | |
| 7 | 2017 | 33 | |
| 8 | 2004 | 32 | |
| 9 | 2021 | 10 | |
| 10 | 2019 | 6 | |
| 11 | 2020 | 2 | |
| 12 | 2024 | 2 | |
| 13 | 2020 | 1 | |
| 14 | 2009 | 1 | |
| 15 | 2022 | 1 | |
| 16 | 2020 | 0 |
About David Luo
David Luo is a scholar working on Health Information Management, Immunology, Neurology, Pulmonary and Respiratory Medicine and Pharmacy, having authored 16 papers that have together received 1.3k indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (3 papers), Lung Cancer Treatments and Mutations (3 papers), Immune Cell Function and Interaction (2 papers), Viral gastroenteritis research and epidemiology (1 paper), Cancer Genomics and Diagnostics (1 paper), Patient Safety and Medication Errors (1 paper), Biomedical Text Mining and Ontologies (1 paper) and Urban Agriculture and Sustainability (1 paper). The work is most often cited by research in Oncology (597 citations), Pulmonary and Respiratory Medicine (609 citations), Cancer Research (260 citations), Pathology and Forensic Medicine (197 citations) and Genetics (103 citations). David Luo has collaborated with scholars based in United States, Italy and China. Frequent co-authors include Pratik S. Multani, Zachary Hornby, Alona Muzikansky, Zongli Zheng, Anna F. Farago, Manish R. Patel, Todd Michael Bauer, Daniel Botelho Costa, Alexander Edward Dela Cruz Drilon and David Michael Jackman. Their work appears in journals such as Frontiers in Immunology, Vaccine, Cancer Discovery, Journal of the National Comprehensive Cancer Network and Journal of Pharmacy Practice and Research.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.